Privia Health Group (NASDAQ:PRVA) Posts Earnings Results, Beats Estimates By $0.11 EPS

Privia Health Group (NASDAQ:PRVA) released its quarterly earnings results on Thursday. The company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.11, FiscalAI reports. The business had revenue of $603.85 million during the quarter, compared to the consensus estimate of $560.99 million. Privia Health Group had a return on equity of 2.81% and a net margin of 0.97%.The business’s revenue was up 25.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.22 EPS.

Here are the key takeaways from Privia Health Group’s conference call:

• Provider and attribution growth: Implemented providers reached 5,535 (+13.6% YoY) and attributed lives hit 1.6M (+26.5% YoY), driving practice collections up 14.6% to $914.8M and providing visible revenue runway for 2026.
• Profitability expansion: Adjusted EBITDA rose 36.3% to $36.7M with EBITDA representing 28.5% of care margin (up 290 bps), and management expects ~20% EBITDA growth at the midpoint of guidance with ~80% conversion to free cash flow.
• Strong balance sheet and reiterated guidance: Ended Q1 with $419.5M cash and no debt, maintained full-year 2026 guidance (raising only attributed-lives range), and signaled capacity to fund organic growth and disciplined M&A.
• M&A and integration progress: The Evolent ACO assets are reported ahead of integration schedule, management says the business-development pipeline is robust and will be used to expand Privia’s multi-state footprint.
• Technology and AI focus: New CTO hire and a push to deploy generative AI across enterprise, care-center, and care-delivery workflows are expected to boost productivity and help push margins toward the high end of long-term targets.

Privia Health Group Stock Down 3.7%

Shares of NASDAQ:PRVA traded down $0.90 during midday trading on Friday, reaching $23.10. The company’s stock had a trading volume of 1,080,445 shares, compared to its average volume of 972,100. The firm has a market cap of $2.90 billion, a price-to-earnings ratio of 144.35, a price-to-earnings-growth ratio of 1.50 and a beta of 0.96. Privia Health Group has a 1 year low of $18.77 and a 1 year high of $26.51. The business has a 50 day moving average price of $22.73 and a 200 day moving average price of $23.34.

Wall Street Analyst Weigh In

PRVA has been the topic of several research reports. Truist Financial increased their price target on shares of Privia Health Group from $31.00 to $33.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Canaccord Genuity Group lowered their target price on Privia Health Group from $35.00 to $34.00 and set a “buy” rating on the stock in a report on Friday. Barclays raised their price target on Privia Health Group from $23.00 to $25.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 25th. Citigroup cut their price target on Privia Health Group from $34.00 to $32.00 and set a “buy” rating for the company in a report on Tuesday, March 3rd. Finally, Jefferies Financial Group restated a “buy” rating and issued a $32.00 price objective on shares of Privia Health Group in a research report on Thursday, February 26th. Eleven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $31.23.

Key Headlines Impacting Privia Health Group

Here are the key news stories impacting Privia Health Group this week:

• Positive Sentiment: Privia Health reported first-quarter results that beat revenue expectations, with sales of $603.85 million versus the $560.99 million estimate, and EPS of $0.19 versus $0.08 expected. The company also said revenue rose 25.8% year over year, and it reiterated full-year 2026 guidance. Article Title
• Positive Sentiment: The company’s updated 2026 outlook calls for revenue of $2.4 billion to $2.5 billion, which is in line with or slightly above market expectations and supports the case for continued growth. Article Title
• Neutral Sentiment: Investors are also parsing the Q1 2026 earnings call transcript and related earnings coverage for management commentary on margins, utilization trends, and the path to hitting full-year targets. Article Title
• Negative Sentiment: Two insider-selling reports may be weighing on sentiment: the CFO sold about $179,690 of stock and a director sold about $427,229 of stock, which can signal caution even when fundamentals are improving. Article Title Article Title

Insiders Place Their Bets

In related news, CFO David Mountcastle sold 1,206 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $25.00, for a total transaction of $30,150.00. Following the completion of the transaction, the chief financial officer owned 214,847 shares of the company’s stock, valued at approximately $5,371,175. This represents a 0.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Parth Mehrotra sold 26,509 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $22.11, for a total transaction of $586,113.99. Following the transaction, the chief executive officer directly owned 555,443 shares in the company, valued at approximately $12,280,844.73. This represents a 4.56% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 274,255 shares of company stock valued at $6,299,092. Insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Quadrant Capital Group LLC grew its position in Privia Health Group by 46.0% during the fourth quarter. Quadrant Capital Group LLC now owns 22,318 shares of the company’s stock valued at $529,000 after acquiring an additional 7,031 shares during the period. Russell Investments Group Ltd. raised its holdings in shares of Privia Health Group by 33,783.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 20,669 shares of the company’s stock worth $515,000 after purchasing an additional 20,608 shares during the period. Vestcor Inc lifted its stake in shares of Privia Health Group by 109.5% in the 3rd quarter. Vestcor Inc now owns 19,638 shares of the company’s stock valued at $489,000 after purchasing an additional 10,265 shares in the last quarter. Elo Mutual Pension Insurance Co purchased a new stake in shares of Privia Health Group during the 4th quarter worth about $478,000. Finally, Vanguard Personalized Indexing Management LLC grew its holdings in shares of Privia Health Group by 5.9% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 16,250 shares of the company’s stock worth $385,000 after purchasing an additional 903 shares during the period. 94.48% of the stock is owned by hedge funds and other institutional investors.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.